Overall verdict
Sell
1.5/10
1-year performance
+6.38%
Score breakdown
Up 6.4% over 1 year, 17% of the 52-week range.
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies ; long-acting peptide MC4R agonists ; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy.
The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Sector
Health Care
Industry
Biotechnology
Primary listing
Lse
United States
CEO
Carl Spana
Founded
1986
Employees
29
Revenue / employee
0 USD
Next earnings
September 25, 2026 (estimated)
Institutional holders
- Driehaus Capital Management LLC8.74%
- Jupiter Topco LLC7.34%
- Logos Global Management LP6.82%
- RA CAPITAL MANAGEMENT, L.P.3.26%
- Balyasny Asset Management L.P.2.16%
- MORGAN STANLEY1.43%
- Opaleye Management Inc.1.07%
- GEODE CAPITAL MANAGEMENT, LLC1.02%
- VANGUARD CAPITAL MANAGEMENT LLC0.99%
- Other institutions3.08%
- Rest of the register64.10%
25 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
27.71 USD
52-week low
5.75 USD
1-year performance
6.38%
Rising
Year-to-date performance
-43.04%
Rising
Drawdown
-65.43%
Major drawdown
Position in the 52-week range
17% of range
Gross margin 99.2%, the company loses 48.5% of its revenue, ROIC -286.0%, ROE -297.2%.
Net margin
-48.50%
Negative
Sector -229.34%|S&P 12.97%
Gross margin
99.24%
Exceptional
Return on equity (ROE)
-297.24%
Negative
Sector -58.11%|S&P 16.52%
Return on invested capital (ROIC)
-286.03%
Negative
Free cash flow margin (FCF)
-116.29%
Negative
Revenue to net income
Growth
0.0/10-100.0% a year over 5.
Revenue (trailing 12 months)
12.9M USD
Revenue growth (1y)
—
Revenue growth (3y)
-100.00%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.3x|S&P 23.0x
Forward P/E (adjusted)
—
EV / EBITDA
—
N/A (loss)
Sector 13.4x|S&P 14.5x
PEG
—
Sector 1.05|S&P 0.86
Market cap
18.3M USD
Financial strength
5.8/10Cash covers 3544.1% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-93.21%
Net cash
Cash
10.2M USD
Cash / market cap
55.60%
Very solid
Cash / total debt
3544.07%
Net cash
Interest coverage
-898.6x
Stretched
Net debt
-9.9M USD
Equity
10.6M USD
Closed daily candles, 2 years
Last close on September 24, 2026: 9.58 USD
- MM2011.13
- MM5010.20
- MM20012.85
- RSI 1443.5
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-4.46%
200-day average slope, 3 months
-37.26%
50-day average slope, 1 month
-10.39%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
8.20 % per day
Volatility change
-17.76%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | -2.31 (3) | -2.43 (2) | 12 (3) | — | -17 (2) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of June 10, 2026.
Same sub-industry: 734 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RCKT | 6.8 | N/A | 332M USD | Not meaningful (loss) | — | — | -4.5 % | 1.4x | -51.4 % | -14.6 % | ||
| 2 | CUV | 6.5 | 6.3 | 294M USD | 12.4x | 36.1 % | -1.0 % | 13.2 % | -6.0x | 8.3 % | -29.0 % | ||
| 3 | XFOR | 4.9 | 2.5 | 308M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -13.3 % | ||
| 4 | IKT | 4.4 | 0.9 | 300M USD | Not meaningful (loss) | — | — | -52.0 % | 2.4x | -14.2 % | 29.6 % | ||
| 5 | CATX | 4.4 | 1.6 | 299M USD | Not meaningful (loss) | -28516.1 % | -72.1 % | -39.2 % | 2.1x | -40.6 % | -21.4 % | ||
| 6 | SANN | 4.0 | 3.5 | 286M USD | Not meaningful (loss) | -63.8 % | 97.3 % | -62.8 % | -2.3x | -15.4 % | 25.2 % | ||
| 7 | ALERS | 3.6 | 4.1 | 287M USD | 51.9x | 2.9 % | 9.1 % | 2.6 % | -0.1x | 1.9 % | -1.4 % | ||
| 8 | AMRN | 3.3 | 3.7 | 290M USD | Not meaningful (loss) | -14.6 % | -42.6 % | -5.9 % | 14.7x | 5.4 % | -12.0 % | ||
| 9 | 0KF3 | 1.5 | N/A | 18.3M USD | Not meaningful (loss) | -48.5 % | — | -286.0 % | — | -82.0 % | 6.4 % |
